Eli Lilly (NYSE:LLY) recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 ...

Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and ...

CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

Approximately 15 million Americans are on a GPL-1 or better known as Ozempic, Wegovy and Zepbound but there will be upcoming ...

That is according to the findings of a study presented on Friday at the European Academy of Neurology congress. The pilot ...

Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.